Page last updated: 2024-11-05

tranexamic acid and ST Elevation Myocardial Infarction

tranexamic acid has been researched along with ST Elevation Myocardial Infarction in 1 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

ST Elevation Myocardial Infarction: A clinical syndrome defined by MYOCARDIAL ISCHEMIA symptoms; persistent elevation in the ST segments of the ELECTROCARDIOGRAM; and release of BIOMARKERS of myocardial NECROSIS (e.g., elevated TROPONIN levels). ST segment elevation in the ECG is often used in determining the treatment protocol (see also NON-ST ELEVATION MYOCARDIAL INFARCTION).

Research Excerpts

ExcerptRelevanceReference
"Tranexamic acid (TXA) is an antifibrinolytic which minimises bleeding and transfusions, with thrombotic risk."5.51Acute ST-elevation myocardial infarction due to in-stent thrombosis after administering tranexamic acid in a high cardiac risk patient. ( Kaptein, YE, 2019)
"Tranexamic acid (TXA) is an antifibrinolytic which minimises bleeding and transfusions, with thrombotic risk."1.51Acute ST-elevation myocardial infarction due to in-stent thrombosis after administering tranexamic acid in a high cardiac risk patient. ( Kaptein, YE, 2019)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kaptein, YE1

Other Studies

1 other study available for tranexamic acid and ST Elevation Myocardial Infarction

ArticleYear
Acute ST-elevation myocardial infarction due to in-stent thrombosis after administering tranexamic acid in a high cardiac risk patient.
    BMJ case reports, 2019, Apr-08, Volume: 12, Issue:4

    Topics: Antifibrinolytic Agents; Drug-Eluting Stents; Humans; Male; Middle Aged; Risk Factors; ST Elevation

2019